If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
Lux Health Tech Acquisition (LUXAU)
Upcoming IPO
Gatos Silver, Inc. (GATO)
Biodesix, Inc. (BDSX)
MediaAlpha, Inc. (MAX)
Root, Inc. (ROOT)
Roman DBDR Tech Acquisition (DBDRU)
Atlas Crest Investment Corp. (ACICU)
Caliber Home Loans, Inc. (HOMS)
Allegro MicroSystems, Inc. (ALGM)
Mavenir plc (MVNR)
Galecto, Inc. (GLTO)
Leslie's Inc (LESL)
AmeriHome, Inc. (AHM)
New Beginnings Acquisition (NBA.U)
Lufax Holding Ltd (LU)
Atea Pharmaceuticals, Inc. (AVIR)
SQZ Biotechnologies Company (SQZ)
Bluescape Opportunities Acquisition (BOAC.U)
Absolute Software (ABST)
Priced IPO
Foghorn Therapeutics Inc. (FHTX)
McAfee Corp. (MCFE)
Guild Holdings Company (GHLD)
Abcam plc (ABCM)
Datto Holding Corp. (MSP)
MingZhu Logistics Holdings (YGMZ)
Opthea Limited (OPT)
Eargo, Inc. (EAR)
Aligos Therapeutics, Inc (ALGS)
Praxis Precision Medicines, Inc. (PRAX)
Tarsus Pharmaceuticals, Inc. (TARS)
Array Technologies, Inc. (ARRY)
MINISO Group Holding Limited (MNSO)
Codiak BioSciences, Inc. (CDAK)
Intrusion Securties Inc. (INTZ)
iHuman Inc. (IH)
Shattuck Labs, Inc. (STTK)
Kronos Bio, Inc. (KRON)
Spruce Biosciences, Inc. (SPRB)
Aziyo Biologics, Inc. (AZYO)
More companies

Inhibrx, Inc. (INBX)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a clinical-stage biotechnology company with a pipeline of novel biologic therapeutic candidates, developed using their protein engineering expertise and proprietary single domain antibody, or sdAb, platform. Their sdAb platform allows them to pursue validated targets with clinical promise, but where other antibody and biologic based approaches have failed. Highly modular, their sdAbs can be combined with precise valencies and multiple specificities, creating therapeutic candidates designed to be capable of enhanced cell signaling, conditional activation or combined synergistic functions. They currently have four programs in ongoing Phase 1 clinical trials, three for the treatment of various cancers, and one for Alpha-1 Antitrypsin Deficiency, or AATD. Their most advanced therapeutic candidate, INBRX-109, is a tetravalent death receptor 5, or DR5, agonist being evaluated in patients diagnosed with chondrosarcoma and mesothelioma, two difficult-to-treat cancers. INBRX-106 is a hexavalent OX40 agonist currently being investigated in patients with locally advanced or metastatic solid tumors. Both INBRX-109 and INBRX-106 programs are designed to achieve target agonism through precise control of therapeutic valency. INBRX-105 targets two proteins, each of which can lead to an enhanced anti-tumor immune response; it is engineered with the goal of improving safety through conditional target agonism.
Biological Products
Mark P. Lappe Mark P. Lappe
Employees Founded
80 2017


Address: 11025 N. Torrey Pines Road, Suite 200 La Jolla, CA 92037

Telephone: (858) 795-4220

Web page:

IPO information

Expected Date 8/19/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $623.2
Revenues (MM) $5.69
Net Income (Loss) (MM) $-74.45


What do you think will happen with the INBX share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 6
Shares Revised (MM) 7
Expected offer amount (MM) $102
Realized offer amount(MM) $119
Jefferies/ Evercore ISI/ Credit Suisse
LifeSci Capital

Sector: Healthcare

Tweets about $INBX

Tweets volume:

RT volume:


Google Trends Stats